Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:
Amy E. DeZern, MD, MHS
Oncology and Medicine
The Johns Hopkins University School of Medicine
Srdan Verstovsek, MD, PhD
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)
Phase I data on mesothelin-targeted CAR T-cell therapy with or without pembrolizumab in malignant pleural cancers, from WCLC 2021 as reported by Clinical Care Options (CCO)
From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals
Clinical Care Options (CCO) commentary in which Dr. Daniel Pollyea provides his strategies for treating patients with myelodysplastic syndrome (MDS)